chain of custody SOP – Clinical Research Made Simple https://www.clinicalstudies.in Trusted Resource for Clinical Trials, Protocols & Progress Thu, 02 Oct 2025 10:52:06 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 SOP for Chain of Identity & Chain of Custody (Cell/Gene) https://www.clinicalstudies.in/sop-for-chain-of-identity-chain-of-custody-cell-gene/ Thu, 02 Oct 2025 10:52:06 +0000 ]]> https://www.clinicalstudies.in/?p=7051 Read More “SOP for Chain of Identity & Chain of Custody (Cell/Gene)” »

]]>
SOP for Chain of Identity & Chain of Custody (Cell/Gene)

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-chain-of-identity-and-chain-of-custody-cell-gene”
},
“headline”: “SOP for Chain of Identity & Chain of Custody (Cell/Gene)”,
“description”: “This SOP establishes procedures for maintaining chain of identity and chain of custody in cell and gene therapy clinical trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP/GMP requirements, covering traceability, custody, product handling, and regulatory oversight.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Chain of Identity & Chain of Custody (Cell/Gene)

SOP No. CR/OPS/111/2025
Supersedes NA
Page No. 1 of 52
Issue Date 26/08/2025
Effective Date 01/09/2025
Review Date 01/09/2026

Purpose

The purpose of this SOP is to define the processes required to maintain Chain of Identity (CoI) and Chain of Custody (CoC) for cell and gene therapy products used in clinical trials. These processes ensure traceability, product integrity, subject safety, and regulatory compliance from collection through administration and follow-up.

Scope

This SOP applies to sponsors, investigators, CROs, laboratories, GMP manufacturing facilities, couriers, and site staff involved in ATMP (Advanced Therapy Medicinal Product) clinical trials. It covers sample collection, labeling, custody transfers, product tracking, custody documentation, and archival of records.

Responsibilities

  • Sponsor: Oversees CoI/CoC processes and ensures regulatory compliance.
  • Investigator: Ensures subject-specific identity verification at site level.
  • GMP Facility: Maintains manufacturing custody records and certificates of analysis.
  • CRO: Monitors CoI/CoC compliance across sites and vendors.
  • Courier: Maintains custody during product transportation.
  • QA: Audits CoI/CoC logs for accuracy and completeness.

Accountability

The Sponsor’s ATMP Quality Lead is accountable for overall compliance with Chain of Identity and Chain of Custody procedures. The Investigator is accountable for subject-level verification prior to administration.

Procedure

1. Chain of Identity (CoI)
1.1 Assign unique subject-specific identifiers at time of collection.
1.2 Verify identifiers at each step: collection, processing, manufacturing, and administration.
1.3 Document in Chain of Identity Log (Annexure-1).

2. Chain of Custody (CoC)
2.1 Record all custody transfers from collection through manufacturing, shipment, storage, and administration.
2.2 Use controlled custody forms signed by transferring and receiving personnel.
2.3 Maintain records in Chain of Custody Log (Annexure-2).

3. Custody Transfer
3.1 At each transfer, verify subject identifier, product batch/lot number, and condition.
3.2 Document signatures, date, and time for both transferring and receiving parties.

4. Manufacturing and Quality Control
4.1 GMP facility verifies CoI before initiating processing.
4.2 Issue Certificate of Analysis linked to subject-specific identifiers.

5. Shipment and Storage
5.1 Use validated containers and cold-chain requirements.
5.2 Record shipment details in Custody Transfer Log (Annexure-3).

6. Administration at Site
6.1 Prior to administration, Investigator verifies subject identifier against CoI records.
6.2 Document in Site Administration Log (Annexure-4).

7. Archiving
7.1 Archive all CoI/CoC records in TMF and ISF.
7.2 Retain per global ATMP regulations (minimum 25 years in some regions).

Abbreviations

  • SOP: Standard Operating Procedure
  • CoI: Chain of Identity
  • CoC: Chain of Custody
  • ATMP: Advanced Therapy Medicinal Products
  • QA: Quality Assurance
  • CRO: Contract Research Organization
  • GMP: Good Manufacturing Practice
  • TMF: Trial Master File
  • ISF: Investigator Site File
  • FDA: Food and Drug Administration
  • EMA: European Medicines Agency
  • CDSCO: Central Drugs Standard Control Organization
  • WHO: World Health Organization

Documents

  1. Chain of Identity Log (Annexure-1)
  2. Chain of Custody Log (Annexure-2)
  3. Custody Transfer Log (Annexure-3)
  4. Site Administration Log (Annexure-4)

References

Version: 1.0

Approval Section

Prepared By Ravi Kumar, ATMP Specialist
Checked By Sunita Reddy, QA Officer
Approved By Dr. Anil Sharma, Head Clinical Operations

Annexures

Annexure-1: Chain of Identity Log

Date Subject ID Sample ID Verified By Status
01/09/2025 S101 S101-C1 Site Coordinator Verified

Annexure-2: Chain of Custody Log

Date Product ID Transferred From Transferred To Signature
02/09/2025 S101-C1 Collection Site Courier Signed

Annexure-3: Custody Transfer Log

Date Product ID Location Responsible Condition
03/09/2025 S101-C1 Manufacturing Facility Technician Acceptable

Annexure-4: Site Administration Log

Date Subject ID Product ID Verified By Administered By
05/09/2025 S101 S101-C1 Investigator Study Nurse

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
26/08/2025 00 Initial version New SOP creation Head Clinical Operations

For more SOPs visit: Pharma SOP

]]>
How to Achieve Maintaining Data Integrity in Sample Transfers with FDA/EMA Oversight https://www.clinicalstudies.in/how-to-achieve-maintaining-data-integrity-in-sample-transfers-with-fda-ema-oversight/ Sun, 28 Sep 2025 16:53:21 +0000 https://www.clinicalstudies.in/?p=7683 Read More “How to Achieve Maintaining Data Integrity in Sample Transfers with FDA/EMA Oversight” »

]]>
How to Achieve Maintaining Data Integrity in Sample Transfers with FDA/EMA Oversight

Maintaining Data Integrity During Sample Transfers in Clinical Trials

Introduction: The Critical Role of Data Integrity in Chain of Custody

Maintaining data integrity during clinical sample transfers is a regulatory imperative. Whether moving biological specimens between sites, labs, or third-party vendors, every handover must be documented, secure, and traceable. The FDA and EMA both expect that all data related to the transfer, condition, and custody of clinical samples uphold ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available).

Chain of custody (CoC) logs serve as the primary documentation tool for sample transfers. However, without robust procedures, data errors can compromise sample validity and study outcomes. This article outlines practical steps and tools to ensure data integrity throughout the sample transfer process and highlights key regulatory touchpoints.

Regulatory References for Sample Transfer Integrity

Global regulators outline several requirements related to custody and data during sample transfers:

  • FDA Guidance on Data Integrity (2018): Emphasizes secure and traceable data during critical processes like sample movement.
  • EMA Reflection Paper on GCP Compliance: Requires complete traceability for biological samples from collection to analysis.
  • ICH E6(R2): Calls for documentation controls to ensure integrity throughout the data lifecycle.

Key Components of Data Integrity in Sample Transfers

Every transfer must include the following data components to be considered compliant:

  • Unique sample identifier (linked to subject and protocol)
  • Date and time of handover with accurate timestamps
  • Sender and receiver names with signatures or electronic approvals
  • Condition of sample at time of transfer (e.g., frozen, ambient)
  • Packaging verification and any temperature-control measures
  • Courier details (if applicable) with tracking number
  • Evidence of receipt by designated personnel at destination

Case Study 1: Break in Chain of Custody Audit Trail

During a Phase II diabetes trial, the EMA observed that the chain of custody log lacked receiver confirmation for a set of urine samples transferred to a central lab. Although the courier manifest was complete, the absence of site-to-courier signature created a break in the audit trail.

CAPA Actions:

  • Updated SOP to mandate dual confirmation (site and courier)
  • Introduced timestamped QR-based handover forms
  • Developed automated audit alerts for incomplete logs

Case Study 2: Data Tampering Risk in Manual Entry

An FDA inspection revealed that paper-based chain of custody logs were editable post-shipment, with no log of who altered the record. Although there was no proven tampering, the lack of access control posed a data integrity risk.

CAPA Implementation:

  • Switched to secure electronic custody system (eCoC)
  • Configured role-based access for data entry and review
  • Enabled audit trails with user ID and timestamps

Table: Data Integrity Risks and Preventive Controls

Data Integrity Risk Impact Preventive Control
Missing timestamps Break in custody trail Mandatory electronic logging with auto-time capture
Unauthorized edits Data falsification potential Role-based eCoC system with locked entries
Courier handover not documented Loss of traceability QR-coded handover forms with mobile app entry

Tools to Support Data Integrity in Custody Documentation

Many sponsors and CROs are turning to validated software platforms to manage custody documentation, including:

  • eCoC systems: Secure digital logs with real-time access and audit trail
  • Courier apps: Handheld tools for scanning sample IDs and capturing GPS/time/location data
  • Sample tracking dashboards: Centralized overview of sample movement and custody status

External Resource

For additional guidance on documentation and chain of custody, refer to Japan’s Clinical Trial Registry Portal.

Conclusion

In today’s decentralized and global trial landscape, ensuring data integrity in sample transfers is non-negotiable. A robust CoC system, supported by electronic documentation, secure handovers, and preventive controls, helps organizations meet FDA and EMA expectations while protecting sample validity. Case studies consistently show that even minor gaps in custody data can lead to major regulatory findings. Proactive SOPs and strong CAPA frameworks are key to maintaining compliance and readiness.

]]>